Kenneth Fischbeck
Branch Chief
National Institute of Neurological Disorders and Stroke
Position in Extended Committee - Preclinical Expert
Kurt is an NIH Distinguished Investigator and Chief of the Neurogenetics Branch at NINDS and a TREAT-NMD STAC member. He has experience with preclinical (animal) studies in various neuromuscular diseases including Duchenne muscular dystrophy, spinal muscular atrophy, and spinal and bulbar muscular atrophy (SBMA), and he has run clinical trials and biomarker studies in Duchenne muscular dystrophy, spinal muscular atrophy, Friedreich\'s ataxia, and SBMA.
He serves on advisory boards for voluntary organizations that are sponsoring similar therapeutics development initiatives, including the SMA Foundation, Target ALS, and MDA Venture Philanthropy. He is also on data and safety monitoring boards for interventional trials in Duchenne muscular dystrophy and giant axonal neuropathy. He has experience with industrial therapeutics development from sabbaticals at Merck and Novartis and from service on advisory boards for Merck, Biogen Idec, Novartis, and other companies.
Neurogenetics Branch, NINDS
35-2A1000, 35 Convent Dr.
Bethesda, MD
20892-3705
United States of America
